Global high-quality reagent supplier
2025.07.02
2025.07.01
2025.07.01
2025.06.30
2025.06.27
2025.06.23
In this article, we'll delve into the secrets of CAS 2639221-78-4. We'll explore its chemical formula, properties, and safety data sheet, unlocking the knowledge you need to navigate its complexities.
In the world of biotechnology and pharmaceutical research, PEG linkers play a vital role in the development of various medical applications. PEG, which stands for polyethylene glycol, is a commonly used linker in drug delivery systems, diagnostics, and biomaterials. These linkers act as bridges that connect different molecules together, improving their stability, solubility, and overall performance.
ADC (Antibody-Drug Conjugates) are a class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. The goal of ADCs is to deliver chemotherapy directly to cancer cells, minimizing the effects on healthy cells and improving the therapeutic index (the ratio of effective dose to toxic dose). They are designed to selectively target cancer cells while sparing normal tissues, making them more effective and less toxic than conventional chemotherapy.
PROTACs (Proteolysis Targeting Chimeras) are a class of molecules that leverage the cell's own protein degradation machinery to selectively eliminate specific proteins. Unlike traditional small-molecule drugs that inhibit the function of proteins, PROTACs induce targeted degradation of proteins that contribute to diseases, including cancer, neurodegenerative diseases, and others.
In order to meet the commercial batch demand of our customers, our production Sichuan Pukang Pharmaceutical Co., Ltd. was established and officially operated in May 2023, which covers a total area of 103.4 acres, with 48 acres of land for the first phase of construction, and a floor area of 15,000 square meters, with three production lines, 38 multi-functional reactors and a series of pilot equipment, to meet the industrialization demand of our customers in an all-round way.
The half-life of a drug determines how long it stays in the body, and a drug with a short half-life can be compensated for by shortening the dosing interval and increasing the dosage administered, but there are cost and safety as well as compliance limitations. Those peptide drugs that have received regulatory approval have significantly higher plasma half-lives of the drug compared to endogenous peptides, providing us with success stories of increasing the in vivo stability of peptides from minutes to hours or longer. Peptide drugs use different chemical structure modification strategies to retard blood or tissue protease-mediated degradation and inactivation, thereby enhancing the drugability of peptide drug candidates.
PuKang Inc.
Zone 1 and 2, 1-3F, Building 3, Chengdu Cross-Strait Science and Technology Industrial Development Park [Jindi Weixin Wenjiang Intelligent Park], Wenjiang District, Chengdu, China.
Tel : +8613708084407
Business/Technical Consulting：
Tel : 008628-82550498 Tel : +8613708084407Order/Customer Service Email：
export@pu-kang.com celeste@pu-kang.com
+8613708084407
